In a troubling revelation, internal records indicate that senior officials from the Trump administration’s Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, last year to discuss the company’s ongoing legal battles regarding glyphosate, the controversial herbicide linked to cancer. This meeting, held on 17 June, raises serious questions about the influence of corporate interests on regulatory decisions that could have widespread implications for public health.
High-Stakes Meeting
The 17 June gathering included key figures from the EPA, including Lee Zeldin, the agency’s administrator, and Nancy Beck, a former senior director at the American Chemistry Council who now serves as the principal deputy assistant administrator for the Office of Chemical Safety and Pollution Prevention. The meeting’s agenda specifically noted discussions about “litigation” and “supreme court action,” signalling a direct engagement with Bayer as the company sought to mitigate the impacts of numerous lawsuits filed by individuals alleging that its glyphosate products, such as Roundup, caused their cancer.
Bayer, facing thousands of lawsuits claiming the company failed to adequately warn users about the cancer risks associated with glyphosate, is keen to have the Supreme Court rule in its favour. Their legal strategy hinges on the argument that if the EPA does not mandate a cancer warning on glyphosate products, Bayer cannot be held liable for failing to provide such warnings. While some courts have sided with Bayer, others have rejected this preemption argument, complicating the company’s legal landscape.
Administration’s Support for Bayer
Since the June meeting, the Trump administration has taken multiple steps that appear to favour Bayer’s position. Notably, on 1 December, D John Sauer, the solicitor general appointed by the Trump administration, filed a brief urging the Supreme Court to hear Bayer’s case. Subsequently, the court agreed to take on the case, scheduling a hearing for 27 April.
Further demonstrating support for Bayer, the White House invoked the Defence Production Act on 18 February, aimed at safeguarding the production of glyphosate while providing immunity to manufacturers like Bayer. On 2 March, Sauer submitted an amicus brief to the Supreme Court, solidifying the government’s backing of Bayer’s argument.
Bayer maintains that the meeting with EPA officials was a standard aspect of the regulatory process, asserting their transparency regarding the ongoing litigation. However, critics point to the disproportionate access that corporate leaders like Anderson have to key decision-makers in government, contrasting it with the lack of engagement with individuals affected by glyphosate.
Industry Influence Over Regulation
Nathan Donley, the environmental health science director for the Center for Biological Diversity, expressed concerns over the apparent prioritisation of corporate interests over public health. “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” he stated, highlighting the implications of such corporate influence on regulatory practices.
Legal experts have echoed these concerns. Whitney Di Bona, a consumer safety advocate, noted the troubling nature of private meetings that focus on limiting corporate liability without offering similar opportunities for those harmed by the products. Naomi Oreskes, a Harvard professor, remarked on the troubling pattern of corporate leaders receiving preferential access to regulatory officials, suggesting a systemic imbalance in how regulatory decisions are influenced.
Zen Honeycutt, founder of Moms Across America, also commented on the situation, indicating that coercive tactics by chemical companies towards regulatory agencies are not new. She contrasted this with the experiences of grassroots organisations, which have struggled to gain traction in advocating for stricter regulations on harmful substances.
Why it Matters
The unfolding scenario surrounding Bayer and the Trump administration raises significant ethical questions about the relationship between corporate interests and public health regulations. As the legal battles over glyphosate continue, the apparent collusion between powerful corporate executives and government regulators underscores a troubling trend where profit motives might overshadow the health and safety of the public. The decisions made in this context will have lasting consequences for environmental policy and individual health, making it imperative to scrutinise the extent of industry influence in regulatory frameworks.
